Natco Pharma Flags 7 FDA Observations at Hyderabad Plant, A Regulatory Red-Flag, Or Procedural Bump?

disclosed that the U.S. FDA wrapped up an inspection at its Kothur (Hyderabad) pharmaceutical unit between June 9–19, 2025, issuing seven Form 483 observations; the company believes these are “procedural in nature” and is confident it can address them promptly. At its Mekaguda API facility (inspected June 9–13, 2025), it received one observation, again classifying it as procedural. While the stock dipped (around 1.2% drop reported), Natco reaffirmed its commitment to cGMP (good manufacturing practices) and supplying high-quality products globally. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.